Table 1.
Baseline characteristics of hepatocellular carcinoma patients with PVTT after propensity score matching.
| Variable | Patients, No. (%) | p value a | ||
|---|---|---|---|---|
| Total (n = 102) | RT-TACE-LEN (n= 51) | TACE-LEN (n= 51) |
||
| Age, median (range), year | 53.5 (18–75) | 54 (18–75) | 53 (27–75) | 0.507 |
| Gender | 0.136 | |||
| Male | 94 (91.3) | 46 (90.2) | 48 (94.1) | |
| Female | 8 (7.8) | 5 (9.8) | 3 (5.9) | |
| Tumor size, cm | 0.650 | |||
| ≤ 5 | 26 (25.2) | 14 (27.5) | 12 (23.5) | |
| > 5 | 76 (73.8) | 37 (72.5) | 39 (76.5) | |
| Tumor, No. | 0.385 | |||
| 1 | 30 (29.1) | 17 (33.3) | 13 (25.5) | |
| ≥ 2 | 72 (69.9) | 34 (66.7) | 38 (74.5) | |
| Portal vein tumor invasion | 0.110 | |||
| I-II grade | 44 (42.7) | 26 (51.0) | 18 (35.5) | |
| III-IV grade | 58 (56.3) | 25 (49.0) | 33 (64.7) | |
| ECOG performance status | 0.750 | |||
| 0 | 91 (88.3) | 45 (88.2) | 46 (90.2) | |
| 1 | 11 (10.7) | 6 (11.8) | 5 (9.8) | |
| Child-Pugh class | 0.799 | |||
| A | 83 (80.6) | 42 (82.4) | 41 (80.4) | |
| B | 19 (18.4) | 9 (17.6) | 10 (19.6) | |
| α-Fetoprotein, ug/L | 0.692 | |||
| ≤ 400 | 54 (52.4) | 28 (54.9) | 26 (51.0) | |
| > 400 | 48 (46.6) | 23 (45.1) | 25 (49.0) | |
| Hepatitis B virus infection | 0.603 | |||
| Negative | 18 (17.5) | 10 (19.6) | 8 (15.7) | |
| Positive | 84 (81.6) | 41 (80.4) | 43 (84.3) | |
| Hepatitis C virus infection | > 0.999 | |||
| Negative | 97 (94.2) | 48 (94.1) | 49 (96.1) | |
| Positive | 5 (4.9) | 3 (5.9) | 2 (3.9) | |
a
Categorical variables were estimated by Chi-square test, and continuous variables were estimated by Student’s t test.
RT, radiation; TACE, trans arterial chemoembolization; LEN, lenvatinib; No., number; ECOG, Eastern Cooperative Oncology Group.